wanyu/IteraTeR_v2 huggingface dataset:
Original:  Pregnant individuals with uterus who have not been on ART prior to delivery or who have been on ART for less than four weeks should also be given intravenous AZT or a single dose of nifedipine (NVD), tenofovir (TDF) and emtricitabine (FTC) and a three-hourly dose of AZT.
Revised:  Pregnant women who have not been on ART prior to delivery or who have been on ART for less than four weeks should also be given intravenous AZT or a single dose of nifedipine (NVD), tenofovir (TDF) and emtricitabine (FTC) and a three-hourly dose of AZT.
Edit intent: clarity
Original:  High viral load (HIV RNA greater than 1000 copies/mL) Unknown viral load Clinical suspicion for maternal noncompliance with prenatal ART regimen Positive rapid HIV antigen/antibody test at labor or prior to a scheduled caesarean delivery Administration of IV Zidovudine can be considered on a case-by-case basis for individuals with uterus who have a moderate viral load (HIV RNA greater than or equal to 50 copies/mL AND less than 1000 copies/mL) near the time of delivery.
Revised:  High viral load (HIV RNA greater than 1000 copies/mL) Unknown viral load Clinical suspicion for maternal noncompliance with prenatal ART regimen Positive rapid HIV antigen/antibody test at labor or prior to a scheduled caesarean delivery Administration of IV Zidovudine can be considered on a case-by-case basis for women who have a moderate viral load (HIV RNA greater than or equal to 50 copies/mL AND less than 1000 copies/mL) near the time of delivery.
Edit intent: clarity
Original:  Further considerations for managing HIV positive individuals with uterus during labor and delivery include the following recommendations to reduce the risk of HIV transmission: Avoid fetal scalp electrodes for fetal monitoring, particularly if the maternal viral load is greater than 50 copies/mL.
Revised:  Further considerations for managing HIV positive women during labor and delivery include the following recommendations to reduce the risk of HIV transmission: Avoid fetal scalp electrodes for fetal monitoring, particularly if the maternal viral load is greater than 50 copies/mL.
Edit intent: clarity
Original:  Avoid artificial rupture of membranes and operative vaginal delivery (using forceps or a vacuum extractor) if at all possible, particularly in individuals with uterus who have not achieved viral suppression.
Revised:  Avoid artificial rupture of membranes and operative vaginal delivery (using forceps or a vacuum extractor) if at all possible, particularly in women who have not achieved viral suppression.
Edit intent: clarity
Original:  Further evaluation The following monitoring tests are recommended for individuals with uterus who are diagnosed with HIV prior to or during pregnancy: HIV Viral Load (via HIV RNA Levels) at the initial prenatal visit, 2–4 weeks after starting or changing ART, monthly until viral load is undetectable, at least every 3 months subsequently throughout pregnancy, and between 34–36 weeks to inform decisions regarding labor and delivery.
Revised:  Further evaluation The following monitoring tests are recommended for women who are diagnosed with HIV prior to or during pregnancy: HIV Viral Load (via HIV RNA Levels) at the initial prenatal visit, 2–4 weeks after starting or changing ART, monthly until viral load is undetectable, at least every 3 months subsequently throughout pregnancy, and between 34–36 weeks to inform decisions regarding labor and delivery.
Edit intent: clarity
Original:  HIV Drug Resistance Testing should be performed prior to initiating ART in any pregnant woman including those who have and have not taken antiretroviral medications before, and when modifying failing ART regimens for pregnant individuals with uterus .
Revised:  HIV Drug Resistance Testing should be performed prior to initiating ART in any pregnant woman including those who have and have not taken antiretroviral medications before, and when modifying failing ART regimens for pregnant women .
Edit intent: clarity
Original:  Hepatitis A, B, and C Screening should be performed in all pregnant individuals with uterus with HIV because coinfection is common.
Revised:  Hepatitis A, B, and C Screening should be performed in all pregnant women with HIV because coinfection is common.
Edit intent: clarity
Original:  Testing for prior Toxoplasma Exposure should be performed in HIV infected pregnant individuals with uterus , as reactivation of Toxoplasma gondii infection can occur with a low CD4 count (less than 100 cells per microliter), and has the potential to cause congenital toxoplasmosis in the fetus, which has many associated birth complications.
Revised:  Testing for prior Toxoplasma Exposure should be performed in HIV infected pregnant women , as reactivation of Toxoplasma gondii infection can occur with a low CD4 count (less than 100 cells per microliter), and has the potential to cause congenital toxoplasmosis in the fetus, which has many associated birth complications.
Edit intent: clarity
Original:  However, the overall benefits of an effective ART regimen outweigh the risks and all individuals with uterus are encouraged to use ART for the duration of their pregnancy.
Revised:  However, the overall benefits of an effective ART regimen outweigh the risks and all women are encouraged to use ART for the duration of their pregnancy.
Edit intent: clarity
Original:  The recommended ART regimen for HIV-positive pregnant individuals with uterus is similar to that of the general population.
Revised:  The recommended ART regimen for HIV-positive pregnant women is similar to that of the general population.
Edit intent: clarity
Original:  For individuals with uterus who are coinfected with hepatitis B, tenofovir with either emtricitabine or lamivudine is the preferred NRTI backbone.
Revised:  For women who are coinfected with hepatitis B, tenofovir with either emtricitabine or lamivudine is the preferred NRTI backbone.
Edit intent: clarity
Original:  Boosted lopinavir has the strongest correlation with this outcome, so individuals with uterus who are at a high risk for premature delivery are advised not to use this drug.
Revised:  Boosted lopinavir has the strongest correlation with this outcome, so women who are at a high risk for premature delivery are advised not to use this drug.
Edit intent: clarity
Original:  They rapidly reduce the viral load and for this reason, they are often used in individuals with uterus who are diagnosed with HIV late in their pregnancy.
Revised:  They rapidly reduce the viral load and for this reason, they are often used in women who are diagnosed with HIV late in their pregnancy.
Edit intent: clarity
Original:  to patients who are at risk of acquiring HIV and are trying to become pregnant, who are pregnant, who are postpartum/breastfeeding /chestfeeding . People who are considered at risk for developing HIV are those who participate in condom-less sex with a partner who is HIV positive, patients who have been diagnosed with a recent sexually transmitted infection (STI), and patients who engage in injection drug use.
Revised:  to patients who are at risk of acquiring HIV and are trying to become pregnant, who are pregnant, who are postpartum/breastfeeding . People who are considered at risk for developing HIV are those who participate in condom-less sex with a partner who is HIV positive, patients who have been diagnosed with a recent sexually transmitted infection (STI), and patients who engage in injection drug use.
Edit intent: fluency
Original:  However, analysis of 5 large studies that utilized Vitamin A supplementation to prevent HIV transmission showed that said supplementation likely has little or no effect on transmission of the virus in pregnant individuals with uterus . Vitamin A supplementation has been largely superseded by antiretroviral therapy on a global basis.
Revised:  However, analysis of 5 large studies that utilized Vitamin A supplementation to prevent HIV transmission showed that said supplementation likely has little or no effect on transmission of the virus in pregnant women . Vitamin A supplementation has been largely superseded by antiretroviral therapy on a global basis.
Edit intent: clarity
Original:  Furthermore, high doses of natural Vitamin A can be toxic to the fetus, which is important to consider in management of HIV in pregnant individuals with uterus . Breastfeeding While maternal compliance with ART reduces the chance of HIV transmission to the infant, there is still a risk of viral transmission via the breastmilk.
Revised:  Furthermore, high doses of natural Vitamin A can be toxic to the fetus, which is important to consider in management of HIV in pregnant women . Breastfeeding While maternal compliance with ART reduces the chance of HIV transmission to the infant, there is still a risk of viral transmission via the breastmilk.
Edit intent: clarity
Original:  Despite these recommendations, some individuals with uterus in developed countries chose to breastfeed.
Revised:  Despite these recommendations, some women in developed countries chose to breastfeed.
Edit intent: clarity
Original:  they should consider HIV prevalence, infant and child mortality rates due to non-HIV causes, current infant and young child feeding, the nutritional status of children, water quality, sanitation resources, and quality of health services. individuals with uterus who breastfeed while receiving ART should exclusively breastfeed their infants for 6 months and then continue breastfeeding for until the infant is 12 months of age.
Revised:  they should consider HIV prevalence, infant and child mortality rates due to non-HIV causes, current infant and young child feeding, the nutritional status of children, water quality, sanitation resources, and quality of health services. women who breastfeed while receiving ART should exclusively breastfeed their infants for 6 months and then continue breastfeeding for until the infant is 12 months of age.
Edit intent: clarity
Original:  Discrimination Despite advances made in preventing transmission, HIV-positive individuals with uterus still face discrimination regarding their reproductive choices.
Revised:  Discrimination Despite advances made in preventing transmission, HIV-positive women still face discrimination regarding their reproductive choices.
Edit intent: clarity
Original:  Health considerations Pregnant individuals with uterus with HIV may still receive the trivalent inactivated influenza vaccine and the tetanus, diphtheria, and pertussis (Tdap) vaccination during pregnancy.
Revised:  Health considerations Pregnant women with HIV may still receive the trivalent inactivated influenza vaccine and the tetanus, diphtheria, and pertussis (Tdap) vaccination during pregnancy.
Edit intent: clarity
Original:  Hepatitis B, hepatitis C, tuberculosis and injection drug use are some of the most common comorbidities associated with HIV. individuals with uterus who screen positive for HIV should also be tested for these conditions so that they may be adequately treated or controlled during the pregnancy.
Revised:  Hepatitis B, hepatitis C, tuberculosis and injection drug use are some of the most common comorbidities associated with HIV. women who screen positive for HIV should also be tested for these conditions so that they may be adequately treated or controlled during the pregnancy.
Edit intent: clarity
Original: The burden of the HIV/AIDS pandemic, including gestational parent-to-child transmission of HIV, disproportionately affects low- and middle-income countries, in particular the countries of Southern Africa.
Revised: The burden of the HIV/AIDS pandemic, including mother-to-child transmission of HIV, disproportionately affects low- and middle-income countries, in particular the countries of Southern Africa.
Edit intent: clarity
Original:  Notably, without antiretroviral medications, obstetrical interventions, and postnatal breastfeeding avoidance, there is approximately a 30\% risk of gestational parent-to-child HIV transmission.
Revised:  Notably, without antiretroviral medications, obstetrical interventions, and postnatal breastfeeding avoidance, there is approximately a 30\% risk of mother-to-child HIV transmission.
Edit intent: clarity
Original:  Mechanism of transmission HIV can be transmitted from an infected gestational parent to the neonate in three circumstances: across the placenta during pregnancy (in utero), at birth due to fetal contact with infected maternal genital secretions and blood, or postnatally through the breast milk.
Revised:  Mechanism of transmission HIV can be transmitted from an infected mother to the neonate in three circumstances: across the placenta during pregnancy (in utero), at birth due to fetal contact with infected maternal genital secretions and blood, or postnatally through the breast milk.
Edit intent: clarity
Original:  It is thought that gestational parent-to-child HIV transmission most commonly occurs at the time of delivery when the baby comes into direct contact with the gestational parent 's infected blood or genital secretions/fluid in the birth canal.
Revised:  It is thought that gestational parent-to-child HIV transmission most commonly occurs at the time of delivery when the baby comes into direct contact with the mother 's infected blood or genital secretions/fluid in the birth canal.
Edit intent: clarity
Original:  Maternal treatment with ART therapy prior to delivery decreases the viral load, or the amount of virus present in the gestational parent 's blood and other body fluids, which significantly reduces the chance of viral transmission to the fetus during labor.
Revised:  Maternal treatment with ART therapy prior to delivery decreases the viral load, or the amount of virus present in the mother 's blood and other body fluids, which significantly reduces the chance of viral transmission to the fetus during labor.
Edit intent: clarity
Original:  However, it is vital for any HIV positive gestational parent to initiate and maintain appropriate ART therapy under the guidance of an HIV expert prior to and throughout pregnancy to reduce the risk of perinatal transmission to the fetus.
Revised:  However, it is vital for any HIV positive mother to initiate and maintain appropriate ART therapy under the guidance of an HIV expert prior to and throughout pregnancy to reduce the risk of perinatal transmission to the fetus.
Edit intent: clarity
Original:  This blood test assesses whether or not the gestational parent has created antibodies, which are disease-fighting proteins of the immune system, against the HIV-1 and HIV-2 viruses.
Revised:  This blood test assesses whether or not the mother has created antibodies, which are disease-fighting proteins of the immune system, against the HIV-1 and HIV-2 viruses.
Edit intent: clarity
Original:  Prevention of gestational parent-to-child transmission The risk of HIV transmission from gestational parent to child is most directly related to the plasma viral load of the gestational parent.
Revised:  Prevention of mother-to-child transmission The risk of HIV transmission from gestational parent to child is most directly related to the plasma viral load of the gestational parent.
Edit intent: clarity
Original:  Prevention of gestational parent-to-child transmission The risk of HIV transmission from gestational parent to child is most directly related to the plasma viral load of the gestational parent.
Revised:  Prevention of gestational parent-to-child transmission The risk of HIV transmission from mother to child is most directly related to the plasma viral load of the gestational parent.
Edit intent: clarity
Original:  Antiretroviral therapy is most importantly used at the following times in pregnancy to reduce the risk of gestational parent-to-child transmission of HIV: During pregnancy: pregnant women infected with HIV receive an oral regimen of at least three different anti-HIV medications.
Revised:  Antiretroviral therapy is most importantly used at the following times in pregnancy to reduce the risk of mother-to-child transmission of HIV: During pregnancy: pregnant women infected with HIV receive an oral regimen of at least three different anti-HIV medications.
Edit intent: clarity
Original:  The viral load helps determine which mode of delivery is safest for both the gestational parent and the baby.
Revised:  The viral load helps determine which mode of delivery is safest for both the mother and the baby.
Edit intent: clarity
Original:  According to the NIH, when the gestational parent has been receiving ART and her viral load is low (HIV RNA less than 1000 copies/mL) at the time of delivery, the risk of viral transmission during childbirth is very low and a vaginal delivery may be performed.
Revised:  According to the NIH, when the mother has been receiving ART and her viral load is low (HIV RNA less than 1000 copies/mL) at the time of delivery, the risk of viral transmission during childbirth is very low and a vaginal delivery may be performed.
Edit intent: clarity
Original:  In these situations, this is the appropriate management guideline regardless of whether or not the gestational parent has taken prenatal ART.
Revised:  In these situations, this is the appropriate management guideline regardless of whether or not the mother has taken prenatal ART.
Edit intent: clarity
Original:  If the rapid screening is positive, intravenous (IV) zidovudine should be initiated in the gestational parent immediately and further confirmatory testing should be performed.
Revised:  If the rapid screening is positive, intravenous (IV) zidovudine should be initiated in the mother immediately and further confirmatory testing should be performed.
Edit intent: clarity
Original:  The potential interactions between the specific ART drugs taken by the gestational parent and those administered during labor should be considered by healthcare providers prior to drug administration.
Revised:  The potential interactions between the specific ART drugs taken by the mother and those administered during labor should be considered by healthcare providers prior to drug administration.
Edit intent: clarity
Original:  Antiretroviral medications The goals of antiretroviral administration during pregnancy are to reduce the risk of transmission of HIV from gestational parent to child, to slow maternal disease progression, and to reduce the risks of maternal opportunistic infection and death.
Revised:  Antiretroviral medications The goals of antiretroviral administration during pregnancy are to reduce the risk of transmission of HIV from mother to child, to slow maternal disease progression, and to reduce the risks of maternal opportunistic infection and death.
Edit intent: clarity
Original:  It is important to choose medications that are as safe as possible for the gestational parent and the fetus, and are effective at decreasing the total viral load.
Revised:  It is important to choose medications that are as safe as possible for the mother and the fetus, and are effective at decreasing the total viral load.
Edit intent: clarity
Original:  PrEP can reduce the risk of both gestational parental and fetal acquisition of HIV.
Revised:  PrEP can reduce the risk of both motheral and fetal acquisition of HIV.
Edit intent: clarity
Original:  Nutritional supplements Vitamin A plays a role in the immune system and has been suggested as a low-cost intervention that could help with preventing gestational parent-to-child transmission of HIV.
Revised:  Nutritional supplements Vitamin A plays a role in the immune system and has been suggested as a low-cost intervention that could help with preventing mother-to-child transmission of HIV.
Edit intent: clarity
Original:  Maternal follow-up The most important component of maternal follow-up for HIV positive gestational parents in the postnatal period is ART.
Revised:  Maternal follow-up The most important component of maternal follow-up for HIV positive mothers in the postnatal period is ART.
Edit intent: clarity
Original:  All gestational parents should continue their antiretroviral medications following hospital discharge, and any changes to their regimens should be made in consultation with the physicians who coordinate their HIV care.
Revised:  All mothers should continue their antiretroviral medications following hospital discharge, and any changes to their regimens should be made in consultation with the physicians who coordinate their HIV care.
Edit intent: clarity
Original:  The NIH also advises that providers should be wary of the unique challenges to medication compliance that gestational parents face in the postpartum period when designing a discharge ART regimen for their patients.
Revised:  The NIH also advises that providers should be wary of the unique challenges to medication compliance that mothers face in the postpartum period when designing a discharge ART regimen for their patients.
Edit intent: clarity
Original:  Newborns who were exposed to HIV in utero and whose gestational parents were on ART prior to and during pregnancy and achieved viral suppression by delivery should be administered zidovudine for 4 weeks to continue preventing HIV transmission following delivery.
Revised:  Newborns who were exposed to HIV in utero and whose mothers were on ART prior to and during pregnancy and achieved viral suppression by delivery should be administered zidovudine for 4 weeks to continue preventing HIV transmission following delivery.
Edit intent: clarity
Original:  the gestational parent was not taking antiretroviral drugs in the pre-pregnancy period or during pregnancy, the gestational parent had not achieved viral suppression, or the gestational parent experienced an acute HIV infection during pregnancy or while breastfeeding), the infant should be started on a presumptive three drug ART regimen for treatment of the infection until the infant's test results are available.
Revised:  the mother was not taking antiretroviral drugs in the pre-pregnancy period or during pregnancy, the gestational parent had not achieved viral suppression, or the gestational parent experienced an acute HIV infection during pregnancy or while breastfeeding), the infant should be started on a presumptive three drug ART regimen for treatment of the infection until the infant's test results are available.
Edit intent: clarity
Original:  the gestational parent was not taking antiretroviral drugs in the pre-pregnancy period or during pregnancy, the gestational parent had not achieved viral suppression, or the gestational parent experienced an acute HIV infection during pregnancy or while breastfeeding), the infant should be started on a presumptive three drug ART regimen for treatment of the infection until the infant's test results are available.
Revised:  the gestational parent was not taking antiretroviral drugs in the pre-pregnancy period or during pregnancy, the mother had not achieved viral suppression, or the gestational parent experienced an acute HIV infection during pregnancy or while breastfeeding), the infant should be started on a presumptive three drug ART regimen for treatment of the infection until the infant's test results are available.
Edit intent: clarity
Original:  the gestational parent was not taking antiretroviral drugs in the pre-pregnancy period or during pregnancy, the gestational parent had not achieved viral suppression, or the gestational parent experienced an acute HIV infection during pregnancy or while breastfeeding), the infant should be started on a presumptive three drug ART regimen for treatment of the infection until the infant's test results are available.
Revised:  the gestational parent was not taking antiretroviral drugs in the pre-pregnancy period or during pregnancy, the gestational parent had not achieved viral suppression, or the mother experienced an acute HIV infection during pregnancy or while breastfeeding), the infant should be started on a presumptive three drug ART regimen for treatment of the infection until the infant's test results are available.
Edit intent: clarity